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Abstract
von Willebrand factor/ristocetin (vWF/R) induces GPIb-dependent platelet agglutination and activation of aIIbb3 integrin,
which also binds vWF. These conditions make it difficult to investigate GPIb-specific signaling pathways in washed platelets.
Here, we investigated the specific mechanisms of GPIb signaling using echicetin-coated polystyrene beads, which
specifically activate GPIb. We compared platelet activation induced by echicetin beads to vWF/R. Human platelets were
stimulated with polystyrene beads coated with increasing amounts of echicetin and platelet activation by echicetin beads
was then investigated to reveal GPIb specific signaling. Echicetin beads induced aIIbb3-dependent aggregation of washed
platelets, while under the same conditions vWF/R treatment led only to aIIbb3-independent platelet agglutination. The
average distance between the echicetin molecules on the polystyrene beads must be less than 7 nm for full platelet
activation, while the total amount of echicetin used for activation is not critical. Echicetin beads induced strong
phosphorylation of several proteins including p38, ERK and PKB. Synergistic signaling via P2Y12 and thromboxane receptor
through secreted ADP and TxA2, respectively, were important for echicetin bead triggered platelet activation. Activation of
PKG by the NO/sGC/cGMP pathway inhibited echicetin bead-induced platelet aggregation. Echicetin-coated beads are
powerful and reliable tools to study signaling in human platelets activated solely via GPIb and GPIb-triggered pathways.
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Introduction
In vivo, von Willebrand Factor (vWF) interacts with platelet
glycoprotein Ib complex (GPIb) under high shear and triggers
platelet activation, which leads to ADP and TxA2 release and
hence aIIbb3 activation and platelet aggregation. Under normal
conditions, vWF does not interact with circulating platelets [1].
Following injury under high shear conditions the globular
molecule of vWF adheres to subendothelial collagen and is
stretched to expose the A1 domains, the binding domain for GPIb
[2]. vWF is a large multimer containing many A1 domains, which
can bind GPIb molecules on the platelet surface [3]. The
clustering of GPIb receptors linked to the submembranous
cytoskeleton triggers platelet activation [4,5]. However, the
number of A1 domains interacting with GPIb on a platelet
surface as well as the distance between neighbouring A1 domains
required for GPIb clustering and platelet activation was not
previously determined.
The antibiotic ristocetin binds to the C-terminal part of the A1-
domain of vWF as well as to GPIb, inducing the interaction
between vWF and GPIb on platelets [6]. However, vWF/R
treatment strongly agglutinates stirred, washed platelets [7].
Agglutination by vWF/R is passive and does not cause intracel-
lular signaling. It takes place even with formaldehyde-fixed
platelets (often used as a clinical test). The C1 domain of vWF
can also interact with aIIbb3 integrin on the platelet surface to
induce an intracellular signal independently from GPIb [8,9]. All
these events caused by vWF/R treatment obscure the analysis of
GPIb receptor signaling. A surface coated with recombinant
dimeric A1 domain was used earlier to study GPIb specific
signaling [10]. However, dimeric A1 domain cannot be used to
activate platelets in suspension via their vWF receptor without
cross linking the A1 domains. Therefore, we developed a new
model for the study of GPIb specific signaling in human platelets
based on echicetin-coated polystyrene beads (EP).
Echicetin, a snake venom C-type lectin, specifically binds to
GPIb, but does not induce activation of washed platelets.
Moreover, binding of echicetin to GPIb completely blocks vWF/
R induced platelet agglutination [11]. However, echicetin can be
cross-linked by plasma IgMk to induce platelet agglutination and
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weak aggregation [12]. A maximum of 10 echicetin molecules can
bind to one IgMk molecule and this complex may not be sufficient
to cluster GPIb molecules to the extent required to activate aIIbb3
and induce full aggregation. Therefore, we used echicetin coated
polystyrene beads with a determined number of GPIb-binding
sites and a known average distance between neighboring echicetin
molecules, and investigated platelet agglutination/aggregation.
We showed that our model can be used to study signaling
mechanisms in platelets specifically activated via GPIb and that for
maximum platelet activation and aggregation the GPIb ligands
should be spaced closer than 7 nm.
Materials and Methods
Ethics Statement
Blood was obtained from healthy volunteers, who gave written
informed consent according to our institutional guidelines and the
Declaration of Helsinki. Our studies with human platelets and the
consent procedure were approved and reconfirmed (September
24, 2008) by the local ethics committee of the University of
Wuerzburg (Studies No. 67/92 and 114/04).
Materials
Echis carinatus sochureki venom was from Latoxan (Valence,
France). Ristocetin was from Biopool (Wicklow, Ireland). vWF
(Haemate HS 1000, vWF activity 2200 IE) was from CSL Behring
(Marburg, Germany). Polystyrene beads (0.46 mm, aqueous
suspension, 10% solids) and phospho–p38 (Thr180/Tyr182) MAPK
antibody were from Sigma (Taufkirchen, Germany). R-phycoer-
ythrin (RPE)-conjugated anti-CD62P antibody was from DAKO
(Glostrup, Denmark). Anti-phosphotyrosine antibody (4 G10) was
from Millipore (Schwalbach, Germany). Phospho-VASP Ser239,
and phospho-ERK (Thr201/Tyr204) antibodies were from Nano-
tools (Teningen, Germany). Antibodies against phospho-PKB
(Thr308), VASP, and p38 were from Cell Signaling (Frankfurt,
Germany).
Preparation of Echicetin-coated Polystyrene Beads
Echicetin was purified as previously described [12]. Polystyrene
beads were washed and coated with echicetin in PBS overnight
followed by washing and blocking with BSA. To obtain different
densities, the beads were coated with 0.3 (EP0.3), 0.2 (EP0.2), 0.1
(EP0.1) and 0.05 (EP0.05) mg/ml echicetin.
Determination of the Amount of Echicetin, and the
Distance between the Echicetin Molecules on the Beads
Echicetin was labeled with I125 using Pierce Iodination Reagent
(Iodogen) with a standard protocol (Thermo Scientific - Pierce,
Rockford, USA). Unreacted I125 was removed from the labeled
protein by gel-filtration on Sephadex G10. Labeled echicetin
(10 mg) was mixed with 1 mg of unlabeled echicetin. This mixture
was used as a stock to prepare 0.3 (EP0.3), 0.2 (EP0.2), 0.1 (EP0.1)
and 0.05 mg/ml (EP0.05) echicetin solutions for adsorption on
polystyrene beads using the same protocol as with unlabeled
protein. The total radioactivity of the samples was measured
before adsorption and the residual radioactivity on polystyrene
beads was measured after adsorption using a gamma-counter. The
amount of adsorbed echicetin was calculated from the ratio
between the total sample radioactivity and the residual radioac-
tivity on the polystyrene beads. We found that 28.2, 23.7, 13.2 and
7.5 mg of echicetin (30.6 kDa) bound to EP0.3, EP0.2, EP0.1 and
EP0.05, respectively. Absorbed echicetin (A) corresponds to
5.761014, 4.861014, 2.761014, and 1.561014 molecules. To find
the average distance between two neighboring echicetin molecules
absorbed on polystyrene beads the total area of all beads in the
suspension was calculated as follows.
Stotal~Sbead|N~0:6644 mm
2|1:877|1010
~1:247|1010 mm2
where Sbead is the surface area of a single bead (0.6644 mm
2 for a
bead with d= 0.46 mm) and N is the total number of beads in the
sample, calculated using an equation supplied by Sigma and
determined to be 1.87761010.
Assuming that echicetin is evenly distributed on the polystyrene
surface, the mean area on the bead occupied by each echicetin
molecule was calculated by the equation: SSingle~Stotal=A, where
Ssingle is the area containing a single molecule, Stotal is the total
area of polystyrene beads covered by echicetin and A is the
number of adsorbed echicetin molecules. For EP0.3, EP0.2, EP0.1
and EP0.05, Ssingle was found to be 21.8, 25.7, 46.2 and 81.2 nm
2
respectively. The distance between two neighboring molecules (D)
was calculated as D~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SSingle
p
and found to be 4.7, 5.1, 6.8 and
9.0 nm for EP0.3, EP0.2, EP0.1 and EP0.05, respectively.
Echicetin molecules per bead were calculated as n=A/N giving
30500, 25800, 14300 and 8170 for EP0.3, EP0.2, EP0.1 and
EP0.05, respectively.
Platelet Aggregation
Human platelets were prepared as previously described [13].
Platelet aggregation was measured using an Apact4004 (LabiTec,
Ahrensburg, Germany) aggregometer. Washed platelets (36108/
ml) were treated with echicetin beads (1% w/w suspension) or
vWF/R under continuous stirring at 1000 rpm and 37uC.
Flow Cytometry
Platelets activated with echicetin beads were taken directly from
the aggregation cuvette and fixed with 1% formaldehyde for
10 min. After centrifugation, platelets were resuspended in PBS/
0.5% BSA, and incubated with RPE-conjugated anti-CD62P
antibody. FACS analysis was performed on a Becton Dickinson
FACScalibur using CELLQuest software, version 3.1f (Becton
Dickinson, Heidelberg, Germany).
Platelet Adhesion and Spreading
Cover slips were coated with various concentrations of
echicetin. Platelet adhesion and spreading on echicetin coated
surfaces were performed as described before [14]. Adhered
platelets were studied under the microscope (Zeiss, Axiovert 200)
at 10006 magnification. Platelet images were captured using a
camera (Diagnostic Instruments, SpotPursuit 23) and VisiView
software.
Western Blot Analysis
For Western blot analysis, 26 Laemmli buffer was directly
added to washed platelets stimulated with echicetin beads or
vWF/R. Platelet proteins were separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and the membranes were
incubated with appropriate primary antibodies. Goat anti-rabbit
or anti-mouse IgG conjugated with horseradish peroxidase were
used as secondary antibodies, followed by ECL detection.
Data Analysis
All experiments were performed at least three times and the
data are expressed as mean 6 SEM. Differences between groups
were analyzed by ANOVA followed by Bonferroni’s test and
GPIb Specific Signaling in Platelets
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Student t-test was used when appropriate. P,0.05 was considered
statistically significant.
Results
Echicetin Beads Induce aIIbb3-dependent Platelet
Aggregation
Elucidation of intracellular signaling mechanisms induced by
vWF/R in washed platelet suspension is limited by strong platelet
agglutination. In PRP, addition of ristocetin induces two waves of
platelet activation; first one is agglutination, and the second
aIIbb3-dependent aggregation (Fig. 1A). Therefore, to examine
GPIb specific signaling in washed platelets suspension, we
introduced a new model of echicetin coated polystyrene beads
(EP). Echicetin was shown to bind specifically to GPIb and to
block platelet interactions with vWF [11,12]. EP, after a short lag-
phase, induced strong platelet aggregation, which was completely
blocked by preincubation with aIIbb3 inhibitor aggrastat, or
echicetin monomer (Fig. 1B). In contrast to PRP, in washed
platelet suspension, agglutination of platelets by vWF/R was
inhibited only by monomeric echicetin, but not by aggrastat
(Fig. 1C).
Neither monomeric echicetin nor BSA coated beads (used as
controls) induce platelet aggregation or agglutination (Fig. 2A). To
elucidate whether the density, or the distance between neighboring
molecules of absorbed echicetin influences the ability of EP to
induce platelet aggregation, polystyrene beads were coated with a
defined concentration of echicetin based on the data obtained with
absorption of I125 labeled echicetin on polystyrene beads (see
methods). First, we established the range of echicetin concentra-
tions (between 1 and 0.01 mg/ml) for coating the beads and found
that maximum aggregation was induced by incubation with
0.3 mg/ml, whereas 0.05 mg/ml did not induce any significant
platelet aggregation. According to our calculations (see methods)
the number of echicetin molecules per bead should be 30500,
25800, 14300 and 8170 in EP0.3, EP0.2, EP0.1, and EP0.05,
respectively and the average distance between the adsorbed
echicetin molecules is 4.7, 5.1, 6.8 and 9.0 nm. Correspondingly,
the total number of echicetin molecules added to platelet samples
were 5.761014, 4.861014, 2.761014, and 1.561014 for EP0.3,
EP0.2, EP0.1, and EP0.05, respectively. There are about 40000
molecules of GPIb per platelet [15] and the total number of GPIb
molecules in 4.66107 platelets used in aggregation experiments
were 1.8461012 approximately, which is comparable with the total
number of echicetin molecules in PE0.05.
The maximum aggregation, 94.665.6% and 94.9610.8% was
obtained when platelets were activated by EP0.3 and EP0.2,
respectively. Slightly less aggregation (86.168.2%) was observed
with EP0.1 (Fig. 2B, 2C). However, EP0.05 did not induce
aggregation (3.261.3%), indicating that the amount, and/or the
distance between echicetin molecules in the beads were not
sufficient for GPIb mediated platelet aggregation. In order to
clarify this, we added 5 times more EP0.05 (7.561014 echicetin
molecules per sample) and still found no significant changes in
platelet aggregation (Fig. 2C). These data suggest that the distance
between the echicetin molecules is critical, but not the total
number of echicetin molecules on the beads used for stimulation.
The average distance between echicetin molecules should be less
than 7 nm for GPIb mediated platelet aggregation.
Echicetin-coated Beads Induce P-selectin Surface
Expression in Human Platelets
Platelet activation induced by echicetin beads was determined
by P-selectin expression on the activated platelets. Though
thrombin and echicetin beads induce full platelet aggregation, P-
selectin expression induced by echicetin beads was significantly less
than in thrombin-stimulated platelets. There were no significant
differences between P-selectin expression levels induced by EP0.3
and EP0.2. P-selectin expression was slightly lower with EP0.1 and
strongly decreased in the case of EP0.05 (Fig. 2D). These data
show that echicetin beads induce alpha-granule secretion, but less
than strong agonists like thrombin.
Platelet Adhesion and Spreading on Echicetin-coated
Surface
To identify whether GPIb-mediated platelet activation induces
platelet adhesion and spreading, washed human platelets were
incubated on cover slips coated with increasing concentrations of
echicetin. We found typical platelet adhesion and spreading on
echicetin coated surfaces and the number of adherent platelets
increased with the density of echicetin coated on the surface
(Figure 3A, B). The area covered by spread platelets was also
Figure 1. Echicetin coated polystyrene beads induce aIIbb3–
dependent aggregation in washed platelets. Representative
aggregation curves of platelet rich plasma stimulated with ristocetin
(A), and washed human platelets stimulated with EP0.1 in the absence
of vWF or fibrinogen (B) or vWF-15 mg/ml and Ristocetin-1 mg/ml (C).
Whenever indicated, platelets were preincubated with echicetin-
monomer (25 mg/ml, 3 min) or aggrastat (1.25 mg/ml, 1 min). Shown
are results of three independent experiments.
doi:10.1371/journal.pone.0093569.g001
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dependent on the concentration of the echicetin coated on the
surface (Figure 3C). These results indicated that GPIb-mediated
platelet activation by echicetin induces platelet adhesion and
spreading.
Echicetin Beads Induce Tyrosine Phosphorylation in
Platelets
Global protein tyrosine phosphorylation is a reliable marker of
activation dependent intracellular signaling. Therefore, we exam-
ined changes in protein tyrosine phosphorylation in platelets
activated by EP0.1. Strongly increased tyrosine phosphorylation of
several proteins was observed in platelets stimulated by EP0.1,
which was partially inhibited by aggrastat (Fig. 4A). This indicates
that GPIb-induced tyrosine phosphorylation is partly mediated by
outside-in integrin signaling most likely via proteins released from
a-granules such as fibrinogen. However, preincubation with
monomeric echicetin completely abolished the increase in tyrosine
phosphorylation induced by EP0.1 (Fig. 4A). In contrast, under
our experimental conditions, activation of platelets with vWF/R
did not trigger any tyrosine phosphorylation (Fig. 4B), which
directly corresponds to the platelet agglutination data (Fig. 1C).
Platelet Aggregation Induced by Echicetin Beads is
Mediated by Src-kinases and SYK
Platelets preincubated with Src-kinase inhibitor (PP2) did not
form aggregates, when stimulated with EP. PP3, an inactive
analog of PP2 did not affect EP-induced platelet aggregation
(Fig. 5A, C). In contrast, PP2 had no effect on vWF/R-induced
platelet agglutination (Fig. 5B, D). GPIb-mediated platelet
signaling was also tested using piceatannol, a SYK specific
inhibitor. Piceatannol strongly inhibits aggregation induced by
echicetin beads (Fig. 5A, C) and had no effect on vWF/R-induced
agglutination (Fig. 5B, D). MAP kinases (p38, ERK) and PKB play
essential role in vWF-stimulated platelet activation [16,17,18].
Therefore, we examined the phosphorylation of p38, ERK and
PKB in EP-activated platelets. EP-induced phosphorylation of
p38, ERK and PKB were completely inhibited in platelets by pre-
incubation with PP2 and piceatannol (Fig. 5E). In contrast, in
vWF/R treated platelets, PKB and MAP kinases were not
Figure 2. The distance between echicetin molecules is critical for inducing platelet activation and aggregation. Washed human
platelets were stimulated with EP under stirring conditions (1000 rpm). BSA coated polystyrene beads were used as negative control. Platelet
aggregation stimulated by EP0.3 was considered as 100%. A. Representative aggregation curves of platelets stimulated with EP0.1, BSA-coated
polystyrene beads, or echicetin-monomer are shown. B. Representative aggregation curves of platelets stimulated with EP0.3, EP0.2, EP0.1, EP0.05 or
5 times concentration of EP0.05 are shown. C. The graph shows the corresponding average values of aggregation from B. D. P-selectin surface
expression on platelets was measured as Mean Fluorescence Intensity (MFI) using RPE-conjugated P-selectin antibody in flow cytometry. Thrombin
(0.05 U/ml) and BSA-coated beads (BSA) were used as positive and negative controls, respectively. Results are mean6SD from 3 independent
experiments. * p,0.05 versus EP0.3, and+p,0.05 versus EP0.1.
doi:10.1371/journal.pone.0093569.g002
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activated and Src kinase and Syk inhibitors inhibited only basal
phosphorylation of these kinases (Fig. 5F).
ADP and TXA2 Signaling are Important for Echicetin Bead
Induced Platelet Activation and Aggregation
Secreted ADP and TXA2 play significant roles in shear-induced
GPIb mediated platelet aggregation [1,19]. Mouse platelets in
suspension stimulated with botrocetin/vWF also required ADP
and TXA2 for aggregation [20,21]. To assess the role of ADP and
TxA2 signaling in EP-induced platelet aggregation, platelets were
pre-incubated with antagonists of P2Y12 (AR-C69931), P2Y1
(MRS-2179) or TxA2 receptor (SQ-29548). AR-C69931 potently
inhibits EP-induced platelet aggregation, whereas MRS-2179 had
only a minimal effect. SQ-29548 strongly reduced EP-induced
platelet aggregation (Fig. 6A, C). However, simultaneous inhibi-
tion of ADP and TXA2 receptors did not significantly differ from
the effect of AR-C69931 alone (data not shown) indicating that
other intracellular mechanisms are involved in EP-induced platelet
aggregation. Pre-treatment with AR-C69931 and SQ-29548
inhibits phosphorylation of PKB, ERK and p38 (Fig. 6E) in EP-
stimulated platelets. In contrast, neither ADP nor TxA2 receptor
antagonists affect vWF-induced platelet agglutination (Fig. 6B, D)
and phosphorylation of PKB, ERK and p38 (Fig. 6F).
NO-dependent Activation of Soluble Guanylate Cyclase
Inhibits Echicetin Beads-induced Platelet Aggregation
Previously, we [22,23] and others [24,25] found that vWF/R
treatment of platelets activates the sGC/cGMP/PKG pathway
and induces VASP phosphorylation. To evaluate whether in this
case VASP phosphorylation is mediated by direct activation via
GPIb or by a complex reaction of vWF/R we used our established
system (echicetin beads) to stimulate platelets. First, we found that
PKG activation by sodium nitroprusside (NO donor) inhibits EP-
induced platelet aggregation by 8367% (Fig. 7A, C). Preincuba-
Figure 3. Platelet adhesion and spreading on echicetin-coated surface. Cover slips were coated with various amounts of echicetin or BSA
(control). Washed human platelets (16107/ml) were incubated on the coated cover slips for 15 min. Following incubation, cover slips were washed to
remove unbound platelets and the adherent platelets were fixed with 1% formaldehyde. The fixed platelets were permeabilized with Triton X-100
and stained with phalloidin-Oregon Green (actin). The stained platelets were analyzed under the microscope (Zeiss, Axiovert 200) at 10006
magnification. The images were captured using a camera (Diagnostic Instruments, SpotPursuit 23) and VisiView software. A. Representative images of
the bright-field (upper panel) and actin staining (lower panel) of the cover slips were shown for each sample. B. The number of adhered platelets was
counted in 10 independent cover slips for each sample. C. Surface area of adhered and spread platelets was measured using VisiView software in 10
independent cover slips for each sample. Results are mean 6 SEM from 3 independent experiments.
doi:10.1371/journal.pone.0093569.g003
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tion with sGC specific inhibitor (ODQ) significantly enhanced
(1263%) EP-induced platelet aggregation (Fig. 7A, C), but had no
effect on vWF/R-induced agglutination (Fig. 7B, D). Second, we
tested whether VASP phosphorylation in vWF/R treated platelets
is mediated by GPIb signaling. We can confirm our previous
finding [22] that vWF/R treatment induces strong PKG activation
and subsequent VASP phosphorylation (Fig. 7F). However,
specific activation of GPIb by EP0.1 does not induce any VASP
phosphorylation (Fig. 7E). These data indicate that vWF/R
induced PKG activation is not directly mediated by GPIb
activation but requires additional signaling pathways induced by
vWF/R.
Discussion
vWF mediated signaling in platelets is complex and involves
several intracellular mechanisms, which play an important role in
the initiation of thrombus formation. The complexity of these
mechanisms is related to the vWF molecule itself and its main
platelet receptor, the GPIb/IX/V complex. vWF has several
domains including the D domain (the binding site for FVIII and
heparin), D’-D3 domain (possible binding site for P-selectin), A3
domain (the binding site for fibrillar collagen type I and III), C1
domain (the binding site for integrin aIIbb3), and A1 domain which
binds GPIb [8]. In addition to vWF, other ligands like
thrombospondin-1 [26] and a-thrombin [27] can bind to GPIb
and induce intracellular signaling independently from vWF.
Numerous approaches including genetically modified mouse
models, various forms of von Willebrand disease, shear-induced
thrombus formation, specific interactions with isolated A1 domain,
etc. have been used for the characterization of vWF-induced
signaling [28]. In models, where platelets are used in suspension
additional modulators such as ristocetin or botrocetin need to be
added to initiate vWF/GPIb mediated platelet response. However,
in all these models identification of specific signaling pathways
mediated solely by vWF/GPIb interactions is extremely difficult
for the following reasons: Apart from GPIb, vWF can bind to
other receptors on the platelet surface and initiate complex
signaling events; vWF/R or vWF/botrocetin, under stirring
conditions (which are important to initiate aggregation of platelet
suspensions), induce strong platelet agglutination, which can
influence intracellular signaling mediated by vWF/GPIb interac-
tion. The degree of agglutination probably depends on the source
of vWF and the experimental conditions. Strong platelet
agglutination (which is independent of integrin aIIbb3) induced
by vWF/R treatment has been described in several papers
[7,29,30,31,32]. In our study, we used Haemate HS (vWF activity
2200IE), which is clinically used as vWF substitute in vWF
deficiencies (von Willebrand diseases). We observed that vWF/R
treatment induces only strong platelet agglutination, which was
not affected by aggrastat (Fig. 1C), inhibitors of Src kinase and
SYK (Fig. 5), ADP and TXA2 receptors (Fig. 6).
The main aim of our study was to develop a GPIb-specific
agonist to investigate the GPIb-mediated signaling events in
platelets without interference from other receptor pathways.
Echicetin, a C-type lectin from snake venom, seems to be
applicable for investigations addressing GPIb specific signaling in
washed platelet suspension. Previously, we had shown that a
maximum of 10 echicetin molecules cross-linked with IgMk can
induce aIIbb3-independent platelet agglutination [12]. The
distance between the echicetin molecules coupled to IgMk is
sufficient to cluster few GPIb molecules that lead to agglutination.
However, this complex did not allow us to find out the distance
between echicetin molecules required to induce aIIbb3 integrin-
dependent platelet aggregation. Therefore, we developed a novel
tool to investigate GPIb-specific activation of aIIbb3 integrin-
dependent platelet aggregation. With this tool, we identified that
the distance between the echicetin molecules (,7 nm), but not the
amount of echicetin is critical to induce GPIb clustering and
GPIb-mediated aIIbb3 integrin activation (Fig. 2). Also, platelet
adhesion and spreading depend on the density of echicetin on the
surface used to activate platelets (Fig. 3). These data strongly
support the hypothesis that clustering of GPIb molecules is an
important factor for the initiation of GPIb-mediated intracellular
signaling.
We then compared the aggregation/agglutination induced by
EP and vWF/R and found, consistent with published data [24,33],
that vWF/R induces strong agglutination in washed platelet
suspension (Fig. 1C), without significant activation of tyrosine
kinases (Fig. 4B). In contrast to washed platelets, in PRP addition
of ristocetin induced the well characterized two waves of platelet
activation; first agglutination, which is insensitive to aggrastat, and
second, aggregation inhibited by aggrastat (Fig. 1A). Whereas EP,
under the same experimental conditions, induces strong global
tyrosine phosphorylation, which was only slightly decreased by
aIIbb3 inhibitor, indicating that most of the intracellular signal is
mediated by activation of GPIb, but not aIIbb3 outside-in
signaling (Fig. 4A). It is important to note that adding echicetin
monomer before stimulation by vWF/R or EP completely
prevents platelet aggregation (Fig. 1B, C) and tyrosine phosphor-
ylation (Fig. 4A). We also investigated several intracellular
signaling pathways downstream of GPIb signaling, and consistent
with others [16,18,24,34], we found that Src kinases, SYK, PKB,
Figure 4. Echicetin beads but not vWF/R induces protein
tyrosine phosphorylation.Washed human platelets were stimulated
with EP0.1 (A) or vWF/R (B) after preincubation with aggrastat (1.25 mg/
ml, 1 min) or echicetin monomer (25 mg/ml, 3 min). Protein tyrosine
phosphorylation was analyzed by Western blot. Shown are represen-
tative blots of three independent experiments.
doi:10.1371/journal.pone.0093569.g004
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p38 and ERK MAP kinases are strongly activated by GPIb
signalling. However, none of these kinases were activated in vWF/
R agglutinated platelets (Fig. 5). We found that P2Y12 and TxA2
signaling plays a synergistic role in EP-induced platelet activation
and aggregation, in line with earlier findings [1,19,20,21] (Fig. 6).
In contrast with other publications [16,21,35], we did not find
significant input from P2Y1 receptor in GPIb-induced platelet
aggregation (Fig. 6). Our data clearly show that P2Y1 receptor has
only a minor role in GPIb signaling. This finding does not imply
that P2Y1 receptors are without a significant role in vWF-
Figure 5. Src-kinases and SYK are downstream effectors of echicetin beads induced platelet activation. Washed human platelets were
preincubated with Src-kinases inhibitor (PP2, 10 mM), an inactive analog (PP3, 10 mM) or Syk inhibitor (piceatannol, 10 mM) before stimulating with
EP0.1 or vWF/R under stirring conditions. Representative aggregation curves of platelets stimulated with EP0.1 (A) or vWF/R (B) are shown. C, D. The
graphs shows corresponding average values of aggregation from A and B. Platelets stimulated with EP0.1 (E) or vWF/R (F) were lysed at the indicated
time and the phosphorylation of PKB, ERK and p38 was analyzed by Western blot. Total p38 served as loading control. Shown are representative blots
of three independent experiments.+p,0.05 versus EP0.1.
doi:10.1371/journal.pone.0093569.g005
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mediated platelet activation. Probably activation of the P2Y1 is
connected with other pathways stimulated by vWF, but not by
GPIb-mediated signaling.
We can clearly confirm previous findings [22,23,24,25,36] that
vWF/R triggers the sGC/cGMP/PKG pathway (Fig. 7F). How-
ever, this pathway is not mediated by GPIb signaling, as we could
show that EP did not increase phosphorylation of VASP (Fig. 7E),
indicating that other, still unresolved mechanisms, connected with
vWF/R are responsible for activation of the sGC/cGMP/PKG
pathway.
In summary, we introduced a new agonist (echicetin coated
polystyrene beads, EP) that activates platelets via clustering of
GPIb without directly involving other receptors. This should allow
the dissection of the complex mechanisms involved in vWF-
induced platelet activation. We show that the distance (less than
7 nm) between GPIb ligands rather than their concentration is
Figure 6. ADP and TxA2 play significant roles in echicetin bead induced platelet aggregation. Washed human platelets were
preincubated with P2Y12 antagonist (AR-C69931; 0.1 mM, 5 min), P2Y1 antagonist (MRS2179; 1 mM, 5 min) or TxA2 receptor antagonist (SQ-29548;
1 mM, 5 min) before EP0.1 or vWF/R stimulation. Representative aggregation curves of platelets stimulated with EP0.1 (A) or vWF/R (B) are shown. C,
D. The graphs shows corresponding average values of aggregation from A and B. Platelets stimulated with EP0.1 (E) or vWF/R (F) were lysed on
indicated time and the phosphorylation of PKB, ERK and p38 was analyzed by Western blot. Representative blots of three independent experiments
are shown.+p,0.05 versus EP0.1.
doi:10.1371/journal.pone.0093569.g006
GPIb Specific Signaling in Platelets
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e93569
critical for platelet activation/aggregation. We propose that
echicetin-coated beads can be a powerful and reliable tool to
study specific GPIb-dependent signaling pathways in platelets.
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